# Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

> **NCT01687257** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 50 (actual)

## Conditions studied

- Hepatitis C
- Cirrhosis
- Portal Hypertension
- With or Without Liver Decompensation

## Interventions

- **DRUG:** SOF
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01687257
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-01
- **Final completion:** 2015-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01687257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01687257, "Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01687257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*